Delivery Order SPE2DB24D2216-SPE2DB25FGPSL
- Not listed
- The Defense Logistics Agency awarded a $29,315.47 delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25 inhalers (60-count unit) on July 31, 2025, with an ultimate completion date of August 1, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $12,545.94 delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 200-62.5-25 inhalers (60-count units) on July 31, 2025, with an ultimate completion date of August 1, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $13,910.27 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25 inhalers (60-count units) with a firm fixed price contract type. This award was made on August 5, 2025, with an ultimate completion date of August 6, 2025, and represents a non-set-aside competitive award. The product will be performed and delivered from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $19,371.24 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count units). The award is non-competitive and utilizes firm fixed-price pricing, with an ultimate completion date of August 18, 2025. This delivery order represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical...
- The Defense Logistics Agency awarded a $18,397.70 delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 200-62.5-25 inhalers (60-count units) on July 24, 2025, with completion expected by July 25, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal healthcare vendor,...
- The Defense Logistics Agency awarded a delivery order valued at $15,182.54 to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 inhalers (60-count units) on August 20, 2025, with a completion date of August 21, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $22,534.20 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25 inhalers (60-count supply). This firm fixed price contract, awarded on August 15, 2025, represents a competitive award with no set-aside designation and will be completed by August 18, 2025. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency awarded a $16,902.11 delivery order to AmerisourceBergen Drug Corp for Trelegy Ellipta 200-62.5-25 inhalers (60-count units) on August 13, 2025, with completion scheduled for August 14, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The pharmaceutical products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,076.77 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25 inhalers (60-count supply). This is a firm fixed-price, competitively awarded contract with no set-aside designation, with an ultimate completion date of July 22, 2025. The award was made to AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania, the company's headquarters location, which also serves as the place of performance for...
- The Defense Logistics Agency (DLA) awarded a $18,604.96 delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 200-62.5-25 inhalers (60-count units) on September 3, 2025, with an ultimate completion date of September 4, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location, where the company's corporate office is headquartered. This delivery order is...
- SPE2DB24D2216Indefinite Delivery Contract
- SPE2DB24D2216-SPE2DB25FGPSLDelivery Order
The Defense Logistics Agency awarded a $19,858.14 delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25 inhalers (60-count supply) under a firm fixed price contract. The award was made on September 3, 2025, with an ultimate completion date of September 4, 2025, and represents a non-competitive delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA Medical Supply Chain. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. TRELEGY ELLIPTA is a combination maintenance inhaler used for chronic obstructive pulmonary disease treatment, reflecting the company's extensive portfolio of specialty medications, brand-name drugs, and medical supplies across multiple therapeutic domains serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $19.9k | 9/3/25 |